On February 28, 2020, Patrick Fabbio provided notice to the Board of Directors of Progenics Pharmaceuticals, Inc. (the Company) of his intention to resign as the Company’s Chief Financial Officer, effective March 27, 2020. Mr. Fabbio has agreed to continue providing services to Progenics as a consultant following the effective date of his resignation until the earlier of the anticipated closing of the Company’s proposed merger with Lantheus Holdings, Inc. or May 15, 2020.